General Updates

July 08, 2026 BSE Limited National Stock Exchange of India Ltd. P. J. Towers, Exchange Plaza, Plot No. C/1, Dalal Street, G Block Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E) Mumbai- 400 051 Scrip Code-540025 Trading Symbol-ADVENZYMES Dear Sir/Madam, Sub: Business Responsibility and Sustainability Report for the financial year 2025-26 Ref.: ISIN: INE837H01020 Pursuant to Regulation 34 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), enclosed is the Business Responsibility and Sustainability Report of the Company, which forms an integral part of the Integrated Annual Report for financial year 2025-26 (FY26) submitted to the Exchanges. The aforesaid Business Responsibility and Sustainability Report FY26 is also uploaded on the website of the Company, under the tab ‘Stock Exchange Compliance’ at – https://www.advancedenzymes.com/wp-content/uploads/2026/07/Business-Responsibility-and- Sustainability-Report-FY26.pdf This is for your information and for public at large. Thanking you, Yours faithfully, For Advanced Enzyme Technologies Limited Sanjay Basantani Company Secretary and Head-Legal Encl: As above CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORT (BRSR) SECTION A: GENERAL DISCLOSURES I. Details of the listed entity 1. Corporate Identification Number (CIN) of the Listed L24200MH1989PLC051018 Entity 2. Name of the Listed Entity Advanced Enzyme Technologies Limited (“AETL”) 3. Year of Incorporation 1989 4. Registered office address 5th Floor, ‘A’ wing, Sun Magnetica, LIC Service Road, 5. Corporate office address Louiswadi, Thane (W) - 400 604, Maharashtra, India 6. E-mail info@advancedenzymes.com 7. Telephone +91-22-4170 3200 8. Website www.advancedenzymes.com 9. Financial year for which the reporting is done FY 2025-26 (April 01, 2025 to March 31, 2026) 10. Name of the Stock Exchange(s) where shares are listed BSE Limited (BSE) & National Stock Exchange of India Limited (NSE) 11. Paid-up Capital ` 223.85 million (as of March 31, 2026) 12. Name and contact details (telephone, email address) of Mr. Ronak Saraf, the person who may be contacted in case of any queries Manager-Investor Relations on the BRSR report ir@advancedenzymes.com; +91 22-4170 3200 13. Reporting Boundary - Are the disclosures under this Disclosures under this report are made on a standalone report made on a standalone basis (i.e. only for the basis for Advanced Enzyme Technologies Limited entity) or on a consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements, taken together) 14. Name of assurance provider NA 15. Type of assurance obtained NA II. Products/services 16. Details of business activities (accounting for 90% of the turnover) S. % of turnover Description of main activity Description of business activity No. of the entity 1. Manufacturing Chemical and chemical products; pharmaceuticals; 100% medicinal chemical and botanical products 17. Products/Services sold by the entity (accounting for 90% of the entity’s turnover) Product/service NIC Code % of total turnover contributed 1. Enzymes and Probiotics 21001 100% III. Operations 18. Number of locations where plants and/or operations/offices of the entity are situated Location Number of plants Number of offices Total National (India) 4 2 6 International - - - Note: AETL has 2 R&D laboratories INTEGRATED ANNUAL REPORT 2025-26 BRSR (CONTD.) 19. Markets served by the entity: a. Number of locations Locations Number National (No. of states) PAN India presence across all 28 states and 8 Union Territories International (No. of countries) Exported to 52 countries across 5 continents Note: During FY 2025-26, the Company dispatched its materials to 20 states and 4 Union Territories b. What is the contribution of exports as a percentage of the total turnover of the entity? Exports account for 33.58% of the revenues. c. A brief on types of customers T he Company provides proprietary enzymes & probiotics products and customized solutions to Human Nutrition, Animal Nutrition, Bio-Processing Industry (Food & Non-Food processing). IV. Employees 20. Details as at the end of financial year: 2025-26 a. Employees and Workers (including differently abled) S. Total Male Female Particulars No. (A) No. (B) % (B/A) No. (C) % (C/A) Employees 1. Permanent (D) 362 278 76.80% 84 23.20% 2. Other than permanent (E) 38 33 86.84% 5 13.16% 3. Total employees (D + E) 400 311 77.75% 89 22.25% Workers 4. Permanent (F) 47 47 100.00% 0 0.00% 5. Other than permanent (G) 315 305 96.83% 10 3.17% 6. Total workers (F + G) 362 352 97.24% 10 2.76% b. Differently abled Employees and Workers S. Male Female Particulars Total (A) No. No. (B) % (B/A) No. (C) % (C/A) Differently Abled Employees 1. Permanent (D) 1 1 100.00% 0 0.00% 2. Other than permanent (E) 0 0 0.00% 0 0.00% 3. Total differently abled Employees (D + E) 1 1 100.00% 0 0.00% Differently Abled Workers 4. Permanent (F) 0 0 0.00% 0 0.00% 5. Other than permanent (G) 0 0 0.00% 0 0.00% 6. Total differently abled Workers (F + G) 0 0 0.00% 0 0.00% 21. Participation/Inclusion/Representation of women No. and Percentage of Females Total (A) No. (B) % (B/A) Board of Directors 9 3 33.33% Key Management Personnel (KMP)* 2 0 0.00% *Note: KMP includes Chief Financial Officer (CFO) and Company Secretary (CS) ADVANCED ENZYME TECHNOLOGIES LIMITED CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS 22. Turnover rate for permanent Employees and Workers FY 2025-26 FY 2024-25 FY 2023-24 Male Female Total Male Female Total Male Female Total Permanent Employees 10.55% 25.16% 14.11% 6.68% 17.02% 9.29% 11.21% 12.40% 11.49% Permanent Workers 2.11% 0.00% 2.11% 3.01% 0.00% 2.94% 7.69% 0.00% 7.69% V. Holding, Subsidiary and Associate companies (including joint ventures) 23. Names of Holding/Subsidiary/Associate companies/Joint Ventures Does the entity Indicate whether indicated at column Holding / % of shares S. Name of the Holding / Subsidiary / A, participate in the Subsidiary / held by No. Associate companies / Joint ventures (A) business responsibility Associate / Joint listed entity initiatives of the listed venture entity? (Yes/No) 1. JC Biotech Private Limited# Subsidiary 96 2. Advanced Bio-Agro Tech Limited Subsidiary 60 3. Advanced EnzyTech Solutions Limited Subsidiary 100 4. Advanced Enzymes USA Subsidiary 100 5. Cal-lndia Foods International Subsidiary 100 (Step-down) 6. Advanced Supplementary Technologies Subsidiary 100 No, the subsidiaries Corporation (Step-down) are separate entities, and hence they follow 7. Enzyme Innovation Inc. Subsidiary 100 Business Responsibility (Step-down) initiatives as per 8. Starya Labs Inc. Subsidiary 100 the laws as may be (Step-down) applicable to them. 9. Advanced Enzymes Europe B.V. Subsidiary 100 10. evoxx technologies GmbH Subsidiary 100 (Step-down) 11. SciTech Specialities Private Limited Subsidiary 51 12. Saiganesh Enzytech Solutions Private Limited Subsidiary 50 13. Advanced Nutrazyme Private Limited* Subsidiary 100 Note: * During the financial year 2025-26, the Board of Directors of Advanced Enzyme Technologies Limited (AETL), has accorded its approval for formation of a subsidiary, Advanced Nutrazyme Private Limited (ANPL). The subsidiary received its certificate of incorporation on 4 July 2025. #Currently holds 95.72% in JC Biotech Private Limited. VI. CSR Details 24. i. Whether CSR is applicable as per section 135 of Companies Act, 2013: Yes ii. Turnover (in million) : ` 4,527.66 million (on standalone basis) iii. Net worth (in million) : ` 7,096.23 million (on standalone basis) INTEGRATED ANNUAL REPORT 2025-26 BRSR (CONTD.) VII. Transparency and Disclosures compliances 25. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on responsible business conduct (“NGRBC”) : Grievance FY 2025-26 FY 2024-25 redressal Stakeholder mechanism in N [Showing first 8,000 characters — download PDF for full document]